CSIMarket
 


Cardiff Oncology inc   (CRDF)
Other Ticker:  
 

Cardiff Oncology Inc 's Working Capital Ratio

CRDF's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Working Capital Ratio deteriorated to 10.07 below Cardiff Oncology Inc 's average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 44 other companies have achieved higher Working Capital Ratio than Cardiff Oncology Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 254 to 415.

Explain Working Capital Ratio
How much in Current Assets CRDF´s has?
What is the value of CRDF´s Current Liabilities?


CRDF Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 10.03 % 8.05 % 24.5 % 18.73 % 70.21 %
Y / Y Current Assets Change -29.94 % -27.22 % -25.07 % -23.84 % -13.08 %
Working Capital Ratio MRQ 10.07 10.99 13.62 15.6 15.82
CRDF's Total Ranking # 415 # 254 # 292 # 262 # 349
Seq. Current Liabilities Change -1.3 % 13 % 4.71 % -5.79 % -3.07 %
Seq. Current Assets Change -9.52 % -8.87 % -8.56 % -7.07 % -6.01 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 45
Healthcare Sector # 188
Overall Market # 415


Working Capital Ratio Statistics
High Average Low
34.2 10.61 0.46
(Jun 30 2021)   (Mar 31 2012)




Financial Statements
Cardiff Oncology Inc 's Current Liabilities $ 8 Millions Visit CRDF's Balance sheet
Cardiff Oncology Inc 's Current Assets $ 84 Millions Visit CRDF's Balance sheet
Source of CRDF's Sales Visit CRDF's Sales by Geography


Cumulative Cardiff Oncology Inc 's Working Capital Ratio

CRDF's Working Capital Ratio for the trailling 12 Months

CRDF Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 10.03 % 8.05 % 24.5 % 18.73 % 70.21 %
Y / Y Current Assets TTM Growth -29.94 % -27.22 % -25.07 % -23.84 % -13.08 %
Working Capital Ratio TTM 12.42 13.9 15.35 17.33 19.32
Total Ranking TTM # 264 # 530 # 198 # 5554 # 53
Seq. Current Liabilities TTM Growth -1.3 % 13 % 4.71 % -5.79 % -3.07 %
Seq. Current Assets TTM Growth -9.52 % -8.87 % -8.56 % -7.07 % -6.01 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the III Quarter 2023 to $8.33 millions, cumulative Working Capital Ratio decreased to 12.42 above the CRDF average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Working Capital Ratio than Cardiff Oncology Inc . While Working Capital Ratio overall ranking has improved so far to 264, from total ranking during the twelve months ending second quarter 2023 at 530.

Explain Working Capital Ratio
How much in Current Assets CRDF´s has?
What is the value of CRDF´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 174
Within the Market # 264


trailing twelve months Working Capital Ratio Statistics
High Average Low
26.88 9.87 1.7
(Dec 31 2021)   (Mar 31 2018)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Apogee Therapeutics inc   24.82 $ 426.421  Millions$ 17.178  Millions
Intensity Therapeutics Inc   22.98 $ 16.635  Millions$ 0.724  Millions
Cullinan Oncology Inc   21.77 $ 476.712  Millions$ 21.897  Millions
Krystal Biotech Inc   21.10 $ 582.128  Millions$ 27.583  Millions
Prokidney Corp  20.01 $ 406.423  Millions$ 20.311  Millions
Graphite Bio Inc   19.05 $ 238.783  Millions$ 12.537  Millions
Tourmaline Bio Inc   18.64 $ 151.047  Millions$ 8.105  Millions
Avrobio Inc   18.47 $ 109.170  Millions$ 5.912  Millions
Compass Therapeutics Inc   18.26 $ 166.584  Millions$ 9.124  Millions
4d Molecular Therapeutics Inc   18.07 $ 328.243  Millions$ 18.163  Millions
Icosavax Inc   18.06 $ 235.307  Millions$ 13.030  Millions
Neumora Therapeutics Inc   18.05 $ 525.735  Millions$ 29.123  Millions
Fusion Pharmaceuticals Inc   17.97 $ 203.265  Millions$ 11.312  Millions
Hillevax Inc   17.58 $ 333.195  Millions$ 18.958  Millions
Relay Therapeutics Inc   16.39 $ 831.798  Millions$ 50.748  Millions
Denali Therapeutics Inc   16.06 $ 1,142.884  Millions$ 71.180  Millions
Crispr Therapeutics Ag  15.83 $ 1,760.586  Millions$ 111.234  Millions
Cabaletta Bio Inc   15.65 $ 166.178  Millions$ 10.616  Millions
Voyager Therapeutics Inc   15.03 $ 261.925  Millions$ 17.427  Millions
Iteos Therapeutics Inc   14.28 $ 619.128  Millions$ 43.349  Millions
Caribou Biosciences Inc   14.27 $ 350.693  Millions$ 24.572  Millions
Aura Biosciences Inc   14.13 $ 153.888  Millions$ 10.894  Millions
Vor Biopharma Inc   14.12 $ 164.438  Millions$ 11.645  Millions
Pharmacyte Biotech Inc   14.08 $ 73.748  Millions$ 5.240  Millions
Vigil Neuroscience Inc   13.79 $ 139.847  Millions$ 10.142  Millions
Molecular Partners Ag  13.35 $ 192.459  Millions$ 14.416  Millions
Anavex Life Sciences Corp   13.29 $ 154.386  Millions$ 11.617  Millions
Elevation Oncology inc   12.99 $ 98.797  Millions$ 7.607  Millions
Ambrx Biopharma Inc   12.80 $ 233.818  Millions$ 18.268  Millions
Replimune Group Inc   12.76 $ 508.175  Millions$ 39.832  Millions

Date modified: 2023-11-03T13:45:20+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com